Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
- PMID: 30885690
- DOI: 10.1016/j.imlet.2019.03.006
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Abstract
The ability of immune checkpoint inhibitors (ICIs) to reactivate the killing function of the immune system to tumor cells has led to long lasting immune response presenting highly promising clinical advances. Recently, immune checkpoint inhibitors related resistance due to the specialized tumor microenvironment has also drawn a widely attention. To overcome resistance to immune checkpoint blockade therapy, understanding the relationship of this type of therapy and tumor microenvironment is necessary and critical. This review will focus on how the tumor environment influences the effectiveness of the immunotherapeutic check inhibitors. Finally, we provide a briefly succinct glimpse into the most exciting pre-clinical discoveries and ongoing clinical trials to overcome the resistance of ICIs.
Keywords: CTLA-4; Cancer immunotherapy; Immune checkpoint blockade resistance; PD-1/PD-L1; Tumor microenvironment.
Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.Front Immunol. 2022 Jan 7;12:799455. doi: 10.3389/fimmu.2021.799455. eCollection 2021. Front Immunol. 2022. PMID: 35069581 Free PMC article. Review.
-
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.J Transl Med. 2024 Aug 9;22(1):751. doi: 10.1186/s12967-024-05552-6. J Transl Med. 2024. PMID: 39123227 Free PMC article. Review.
-
Immune-Checkpoint Blockade Therapy in Lymphoma.Int J Mol Sci. 2020 Jul 30;21(15):5456. doi: 10.3390/ijms21155456. Int J Mol Sci. 2020. PMID: 32751706 Free PMC article. Review.
-
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15. Drug Resist Updat. 2020. PMID: 32736034 Review.
-
Treg-mediated acquired resistance to immune checkpoint inhibitors.Cancer Lett. 2019 Aug 10;457:168-179. doi: 10.1016/j.canlet.2019.05.003. Epub 2019 May 9. Cancer Lett. 2019. PMID: 31078738 Review.
Cited by
-
Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study.Hum Vaccin Immunother. 2024 Dec 31;20(1):2423479. doi: 10.1080/21645515.2024.2423479. Epub 2024 Nov 4. Hum Vaccin Immunother. 2024. PMID: 39494935 Free PMC article.
-
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis.Front Oncol. 2024 Jun 11;14:1399544. doi: 10.3389/fonc.2024.1399544. eCollection 2024. Front Oncol. 2024. PMID: 38919533 Free PMC article. Review.
-
CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.J Exp Clin Cancer Res. 2024 May 3;43(1):134. doi: 10.1186/s13046-024-03046-3. J Exp Clin Cancer Res. 2024. PMID: 38698468 Free PMC article.
-
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.MedComm (2020). 2023 Dec 2;4(6):e427. doi: 10.1002/mco2.427. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38045829 Free PMC article. Review.
-
Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy.Theranostics. 2023 Jan 1;13(1):40-58. doi: 10.7150/thno.77233. eCollection 2023. Theranostics. 2023. PMID: 36593951 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials